The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35)

References

• Furtado, P.B., Huang, C.Y., Ihyembe, D., et al. The partly folded back solution structure arrangement of the 30 scr domains in human complement receptor type 1 (cr1) permits access to its C3b and C4b ligands. J. Mol. Biol. 2008, 375, 102–118.
   PubMed Web of Science ®Google Scholar
• Ahearn, J.M., Fearon, D.T. Structure and function of the complement receptor CR1 (CD35) and CR2 (CD21). Adv. Immunol. 1989, 46, 183–219.
   PubMed Web of Science ®Google Scholar
• Delibrias, C., Fischer, E., Kazatchkine, M.D. Receptors for human C3 fragments. In: Rother, K., Till, G.O., Hansch, G.M. (Eds.), The Complement System. Springer, Berlin: Springer, 1997; 211–220.
   Google Scholar
• Wagner, C., Ochmann, C., Schoels, M., et al. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in human T-lymphocytes. Molec. Immunol. 2006, 43, 643–651.
   PubMedGoogle Scholar
• Ghiran, I., Barbashov, S.F., Klickstein, L.B., et al. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J. Exp. Med. 2000, 192, 1797–1808.
   PubMedGoogle Scholar
• Tas, S., Klickstein, L.B., Barbashov, S.F., Nicholson-Weller, A. C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J. Immunol. 1999, 136, 5056–5063.
   Google Scholar
• Walport, M. J. Complement. Second of two parts. N. Engl. J. Med. 2001, 344, 1140–1144.
   PubMed Web of Science ®Google Scholar
• Walport, M. J. Complement. First of two parts. N. Engl. J. Med. 2001, 344, 1058–1066.
   PubMed Web of Science ®Google Scholar
• Michael Kirschfink, M., Mollnes, T.E. Modern Complement Analysis. Clin.Diag. Lab. Immunol. 2003, 10(6), 982–989.
   PubMedGoogle Scholar
• Liu, D., Zhu, J.Y., Niu, Z.X. Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2. Clin. Vacc. Immunol. 2008, 15(6), 901–910.
   PubMedGoogle Scholar
• Gasque, P. Complement: A unique innate immune sensor for danger signals. Molec. Immunol. 2004, 41, 1089–1098.
   PubMed Web of Science ®Google Scholar
• Farries, T.C., Lachmann, P.J., Harrison, R.A. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products. Biochem. J. 1988, 252, 47–54.
   PubMedGoogle Scholar
• Gewurz, H., Ying, S.C., Jiang, H., Lint, T.F. Nonimmune activation of the classical complement pathway. Behring Inst. Mitt. 1993, 93, 138–147.
   Google Scholar
• Kilpatrick, J.M.,Volanakis, J.E. Molecular genetics, structure, and function of C-reactive protein. Immunol. Res. 1991, 10, 43–53.
   PubMedGoogle Scholar
• Armstrong, P.B., Armstrong, M.T., Quigley, J.P. Involvement of alpha 2-macroglobulin and C-reactive protein in a complement-like hemolytic system in the arthropod, Limulus polyphemus. Mol. Immunol. 1993, 30, 929–934.
   PubMedGoogle Scholar
• Liu, T.Y., Minetti, C.A., Fortes-Dias, C.L., et al. C-reactive proteins, limunectin, lipopolysaccharide-binding protein, and coagulin, molecules with lectin and agglutinin activities from Limulus polyphemus. Ann. N.Y. Acad. Sci. 1994, 712, 146–154.
   PubMedGoogle Scholar
• Tharia, H.A., Shrive, A.K., Mills, J.D., et al. Complete cDNA sequence of SAP-like pentraxin from Limulus polyphemus: Implications for pentraxin evolution. J. Mol. Biol. 2002, 316, 583–597.
   PubMedGoogle Scholar
• Bharadwaj, D., Stein, M.P., Volzer, M., et al. The major receptor for C-reactive protein on leukocytes is fcgamma receptor II. J. Exp. Med. 1999, 190, 585–590.
   PubMed Web of Science ®Google Scholar
• Jack, D.L., Klein, N.J., Turner, M.W. Mannose-binding lectin: Targeting the microbial world for complement attack and opsonophagocytosis. Immunol. Rev. 2001,180, 86–99.
   PubMed Web of Science ®Google Scholar
• Petersen, S.V., Thiel, S., Jensenius, J.C. The mannan-binding lectin pathway of complement activation: Biology and disease association. Mol. Immunol. 2001,38, 133–149.
   PubMed Web of Science ®Google Scholar
• Fujita, T., Matsushita, M., Endo, Y. The lectin-complement pathway—Its role in innate immunity and evolution. Immunol. Rev. 2004, 198, 185–202.
   PubMed Web of Science ®Google Scholar
• Matsushita, M., Endo, Y., and Fujita, T. Complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J. Immunol. 2000, 164, 2281–2284.
   PubMed Web of Science ®Google Scholar
• Reid, K.B.M., Turner, M.W. Mammalian lectins in activation and clearance mechanisms involving the complement system. Springer Semin. Immunopathol. 1994, 15, 307–325.
   PubMedGoogle Scholar
• Calender, A., Billaud, M., Aubry, J.P., et al.. Epstein-Barr virus EBV induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 8060–8064.
   PubMed Web of Science ®Google Scholar
• Malhotra, R., Wormald, M.R., Rudd, P.M., et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1995, 1, 237–243.
   PubMed Web of Science ®Google Scholar
• Selander, B., Martensson, U., Weintraub, A., et al. Mannanbinding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 2006, 116, 1423–1434.
   Google Scholar
• Dahl, M.R., Thiel, S., Matsushita, M., et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity 2001, 15, 127–135.
   PubMed Web of Science ®Google Scholar
• Rossi, V., Cseh, S., Bally, I., et al. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J. Biol. Chem. 2001, 276, 40880–40887.
   PubMedGoogle Scholar
• Stover, C., Endo, Y., Takahashi, M., et al. The human gene for mannanbinding lectin-associated serine protease-2 (MASP-2), the effector component of the lectin route of complement activation, is part of a tightly linked gene cluster on chromosome 1p36.2-3. Genes Immun. 2001, 2, 119–127.
   PubMedGoogle Scholar
• Boackle, S.A. Complement and autoimmunity. Biomed.Pharmacother. 2003, 57, 269–273.
   PubMedGoogle Scholar
• Petty, H.R., Worth, R.G., Todd, R.R. Interactions of integrins with their partner proteins in leukocyte membranes. Immunol. Res. 2002, 25, 75– 95.
   PubMedGoogle Scholar
• Dykman, T.R., Cole, J.L., Iida, K., Atkinson, J.P. Polymorphism of human erythrocyte C3b/C4b receptor, Proc. Natl. Acad. Sci. U.S.A. 1983, 80,1698–1702.
   PubMed Web of Science ®Google Scholar
• Dykman, T.R., Hatch, J.A., Aqua, M.S., Atkinson, J.P. Polymorphism of the C3b/C4b (CR1) receptor: Characterization of a fourth allele, J. Immunol. 1985, 134,1787.
   Google Scholar
• Dykman, T.R., Hatch, J.A., Atkinson, J.P. Polymorphism of the human C3b/C4b receptor. Identification of a third allele and analysis of receptor phenotypes in families and patients with systemic lupus erythematosus, J. Exp. Med. 1984, 159, 691–703.
   PubMedGoogle Scholar
• Wong, W.W., Wilson, J.G., Fearon, D.T. Genetic regulation of a structural polymorphism of human C3b receptor, J. Clin. Invest. 1983, 72, 685–693.
   Google Scholar
• Fearon, D.T., Ahearn, JM. Complement receptor type 1 (C3b/C4b receptor; Cd35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21), Curr. Top. Microbiol. Immunol. 1989, 153,83–98.
   Google Scholar
• Fearon, D.T., Wong, W.W. Complement ligand-receptor interactions that mediate biological responses. Annu. Rev. Immunol. 1983, 1, 243–271.
   PubMed Web of Science ®Google Scholar
• Funkhouser, T., Vik, D.P. Promoter activity of the 5’ flanking region of the complement receptor type 1 (CR1) gene: Basal and induced transcription. Biochim. Biophys. Acta 2000, 1490, 99–105.
   PubMedGoogle Scholar
• Ahearn, J.M., Fischer, M.B., Croix, D.A., et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996, 4, 251–262.
   PubMed Web of Science ®Google Scholar
• Carroll, M.C. The role of complement in B cell activation and tolerance. Adv. Immunol. 2000, 74, 61–88.
   PubMedGoogle Scholar
• Haas, K.M., Hasegawa, M., Steeber, D.A., et al. Complement receptors CD21/35 link innate and protective immunity during Streptococcus pneumoniae infection by regulating IgG3 antibody responses. Immunity 2002, 17, 713–723.
   PubMed Web of Science ®Google Scholar
• Molina, H., Holers, V.M., Li, B., et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 3357–3361.
   PubMed Web of Science ®Google Scholar
• Fairweather, D., Frisancho-Kiss, S., Njoku, D.B., et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3- induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J. Immunol. 2006, 176, 3516–3524.
   PubMedGoogle Scholar
• Kaya, Z., Afanasyeva, M., Wang, Y., et al. Contribution of the innate immune system to autoimmune myocarditis: A role for complement. Nat. Immunol. 2001, 2, 739–745.
   PubMed Web of Science ®Google Scholar
• Pratt, J.R., Abe, K., Miyazaki, M., et al. In situ localization of C3 synthesis in experimental acute renal allograft rejection. Am. J. Pathol. 2000, 157, 825–831.
   PubMedGoogle Scholar
• Helmy, K.Y., Katschke, K.J., Gorgani, N.N., et al. CRIg: A macrophage complement receptor required for phagocytosis and circulating pathogens. Cell 2006, 124, 915–927.
   PubMed Web of Science ®Google Scholar
• Avirutnan, P., Mehlhop, E., Diamond, M.S. Complement and its role in protection and pathogenesis of flavivirus infections. Vaccine 2008, 26S 1100–1107.
   Google Scholar
• Holers, V.M. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 2003, 107, 140–151.
   PubMed Web of Science ®Google Scholar
• Thurman, J.M., Holers, V.M. The central role of the alternative complement pathway in human disease. J. Immunol. 2006, 176, 1305–1310.
   PubMed Web of Science ®Google Scholar
• Fingeroth, J.D., Weis, J.J., Tedder, T.F., et al. Epstein–Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 4510–4514.
   PubMed Web of Science ®Google Scholar
• Holers, V.M. Complement receptors and the shaping of the natural antibody repertoire. Springer Sem. Immunopathol. 2005, 26, 405–423.
   PubMed Web of Science ®Google Scholar
• Holers, V.M., Carroll, M.C., Holers, V.M. Innate Autoimmun. Adv. Immunol. 2005, 86, 137–157.
   PubMedGoogle Scholar
• Reid, R.R., Woodstock, S., Shimabukuro-Vornhagen, A., et al. Functional activity of natural antibody is altered in Cr2-deficient mice. J. Immunol. 2002, 169, 5433–5440.
   PubMed Web of Science ®Google Scholar
• Zhang, M., Alicot, E.M., Chiu, I., et al. Identification of the target self antigens in reperfusion injury. J. Exp. Med. 2006, 203, 141–152.
   PubMed Web of Science ®Google Scholar
• Zhang, M., Austen Jr., W.G., Chiu, I., et al. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3886– 3891.
   PubMed Web of Science ®Google Scholar
• Erdei, A., Prechl, J., Isaak, A., Molnar, E. Regulation of B-cell activation by complement receptors CD21 and CD35. Curr. Pharm. Des. 2003, 9, 1849– 1860.
   PubMedGoogle Scholar
• Fearon, D.T. The complement system and adaptive immunity. Immunology 1998, 10, 355–361.
   Google Scholar
• Fang, Y., Xu, C., Fu, Y.X., et al. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J. Immunol. 1998, 160, 5273–5279.
   PubMed Web of Science ®Google Scholar
• Rodgaard, A., Christensen, L.D., Thomsen, B.S., et al. Complement receptor type 1 (CR1, CD35) expression on peripheral T lymphocytes: Both CD4- and CD8-positive cells express CR1. Complement. Inflamm. 1991, 8, 303–309.
   PubMedGoogle Scholar
• Weiss, L., Fischer, E., Haeffner-Cavaillon, N., et al. The human C3b receptor (CR1). Adv. Nephrol. Necker Hosp. 1989, 18, 249–269.
   PubMedGoogle Scholar
• Danielsson, C., Pascual, M., French, L., et al. Soluble complement receptor type 1 (CD35) is released from leukocytes by surface cleavage. Eur. J. Immunol. 1994, 24, 2725–2731.
   PubMed Web of Science ®Google Scholar
• Pascual, M., Steiger, G., Sadallah, S., et al. Identification of membrane-bound CR1 (CD35) in human urine: Evidence for its release by glomerular podocytes. J. Exp. Med. 1994, 179, 889–899.
   PubMedGoogle Scholar
• Weis, J.H., Morton, C.C., Bruns, G.A.P., et al. A complement receptor locus: Genes encoding C3b/C4b receptor and Cad/Epstein-Barr virus receptor map to 1g32. J. Immunol. 1987, 138, 312.
   PubMed Web of Science ®Google Scholar
• Rodriguez de Cordoba, S., Rubinstein, P. Quantitative variations of the C3b/C4b receptor (CR1) in human erythrocytes are controlled by genes within the regulator of complement activation (RCA) gene cluster. J. Exp. Med. 1986, 164, 1274–1283.
   PubMed Web of Science ®Google Scholar
• Krych-Goldberg, M., Atkinson, J.P. Structure-function relationships of complement receptor type 1. Immunol. Rev. 2001, 180, 112–122
   PubMed Web of Science ®Google Scholar
• Krych-Goldberg, M., Moulds, J.M., Atkinson, J.P. Human complement receptor type 1 (CR1) binds to a major malarial adhesin. TRENDS in Molec. Med. 2002, 8 (11), 31–37.
   PubMedGoogle Scholar
• Lublin, D.M., Griffith, R.C., Atkinson, J.P. Influence of glycosylation on allelic and cell-specific Mr variation, receptor processing, and ligand binding of the human complement C3b/C4b receptor. J. Biol. Chem. 1986, 261, 5736–5744.
   PubMedGoogle Scholar
• Wong, W.W., Kennedy, C.A., Bonaccio, E.T., et al. Analysis of multiple restriction fragment length polymorphisms of the gene for the human complement receptor type I. Duplication of genomic sequences occurs in association with a high molecular mass receptor allotype. J. Exp. Med. 1986, 164, 1531–1546.
   PubMedGoogle Scholar
• Holers, V.M., Chaplin, D.D., Leykam, J.F., et al. Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 2459–2463.
   PubMedGoogle Scholar
• Van Dyne, S., Holers, V.M., Lublin, D.M., et al. The polymorphism of the C3b/C4b receptor in the normal population and in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 1987, 68, 570–579.
   PubMed Web of Science ®Google Scholar
• Moulds, J.M., Reveille, J.D., Arnett, F.C. Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups. Clin. Exp. Immunol. 1996, 105, 302–305.
   PubMed Web of Science ®Google Scholar
• Katyal, M., Sivasankar, B., Ayub, S., Das, N. Genetic and structural polymorphism of complement receptor 1 in normal Indian subjects. Immunol. Lett. 2003, 89, 93–98.
   PubMedGoogle Scholar
• Birmingham, D.J., Chen, W., Liang, G., et al. A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology 2003, 108, 531–538.
   PubMedGoogle Scholar
• Xiang, L., Rundles, J.R., Hamilton, D.R., Wilson, J.G. Quantitative alleles of CR1: Coding sequence analysis and comparison of haplotypes in two ethnic groups. J. Immunol. 1999, 163, 4939–4945.
   PubMedGoogle Scholar
• Thomas, B.N., Donvito, B., Cockburn, I., et al. A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa. Genes Immun. 2005, 6, 31–36.
   PubMedGoogle Scholar
• Wilson, J.G., Wong, W.W., Schur, P.H., Fearon, D.T. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N. Engl. J. Med. 1982, 307, 981–986.
   PubMed Web of Science ®Google Scholar
• Wilson, J.G., Ratnoff, W.D., Schur, P.H., Fearon, D.T. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum. 1986, 29, 739–747.
   PubMedGoogle Scholar
• Wilson, J.G., Wong, W.W., Murphy III, E.E., et al. Deficiency of the C3b/C4b receptor (CR1) of erythrocytes in systemic lupus erythematosus: Analysis of the stability of the defect and of a restriction fragment length polymorphism of the CR1 gene. J. Immunol. 1987, 138, 2708–2710.
   PubMedGoogle Scholar
• Rowe, J.A., Raza, A., Diallo, D.A., et al. Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans: Implications for studies on malaria susceptibility. Genes Immun. 2002, 3, 497–500.
   PubMedGoogle Scholar
• Moulds, M.K. Serological investigation and clinical significance of high-titer, low-avidity (HTLA) antibodies. Am. J. Med. Technol. 1981, 47, 789–795.
   PubMedGoogle Scholar
• Daniels, G.L., Anstee, D.J., Cartron, J.P., et al. Blood group terminology 1995. ISBT working party on terminology for red cell surface antigens. Vox Sang 1995, 69, 265–279.
   PubMedGoogle Scholar
• Moulds, J.M., Nickells, M.W., Moulds, J.J., et al. The C3b/C4b receptor is recognized by the Knops, McCoy, Swain-Langley, and York blood group antisera. J. Exp. Med. 1991, 173, 1159–1163.
   PubMedGoogle Scholar
• Rao, N., Ferguson, D.J., Lee, S.F., Telen, M.J. Identification of human erythrocyte blood group antigens on the C3b/C4b receptor. J. Immunol. 1991,146, 3502–3507.
   PubMedGoogle Scholar
• Moulds, J.M., Zimmerman, P.A., Doumbo, O.K., et al. Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1. Blood 2001, 97, 2879–2885.
   PubMed Web of Science ®Google Scholar
• Tamasauskas, D., Powell, V., Schawalder, A., Yazdanbakhsh, K. Localization of Knops system antigens in the long homologous repeats of complement receptor 1. Transfusion 2001, 41, 1397–1404.
   PubMedGoogle Scholar
• Moulds, J.M. Understanding the Knops blood group and its role in malaria. Vox Sang 2002, 83 (Suppl. 1), 185–188.
   PubMedGoogle Scholar
• Moulds, J.M., Thomas, B.J., Doumbo, O., et al. Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion 2004, 44, 164–169.
   PubMed Web of Science ®Google Scholar
• Moulds, J.M., Moulds, J.J., Brown, M., Atkinson, J.P. Antiglobulin testing for CR1-related (Knops/McCoy/Swain–Langley/York) blood group antigens: Negative and weak reactions are caused by variable expression of CR1. Vox Sang 1992, 62, 230–235.
   PubMedGoogle Scholar
• Andrásfalvy, M., Prechl, J., Hardy, T., et al. Mucosal type mast cells express complement receptor type 2 (CD21). Immunol. Lett. 2002, 82, 29–34.
   PubMedGoogle Scholar
• Barrington, R.A., Pozdnyakova, O., Zafari, M.R., et al. Blymphocytememory: Role of stromal cell complement and FcgammaRIIB receptors. J. Exp. Med. 2002, 196(9), 1189–99.
   PubMedGoogle Scholar
• Fischer, M.B., Goerg, S., Shen, L., et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998, 280(5363), 582–5.
   PubMedGoogle Scholar
• Wu, X., Jiang, N., Fang, Y.F., et al. Impaired affinity maturation in Cr2−/− mice is rescued by adjuvants without improvement in germinal center development. J. Immunol. 2000, 165(6), 3119–27.
   PubMedGoogle Scholar
• Fearon, D.T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 1980, 152(1), 20–30.
   PubMedGoogle Scholar
• Klickstein, L.B., Barbashov, S.F., Liu, T., et al. Complement receptor type 1 (CR1 CD35) is a receptor for C1q. Immunity 1997, 7(3), 345–55.
   PubMedGoogle Scholar
• Tedder, T.F., Fearon, D.T., Gartland, G.L., Cooper, M.D. Expression of C3b receptors on human be cells and myelomonocytic cells but not natural killer cells. J. Immunol. 1983, 130(4), 1668–73.
   PubMedGoogle Scholar
• Bogers, W.M., Stad, R.K., Van Es, L.A., Daha, M.R. Both Kupffer cells and liver endothelial cells play an important role in the clearance of IgA and IgG immune complexes. Res. Immunol. 1992, 143(2), 219–24.
   PubMedGoogle Scholar
• Craig, M.L., Bankovich, A.J., McElhenny, J.L., Taylor, R.P. Clearance of antidouble-stranded DNA antibodies: The natural immune complex clearance mechanism. Arthritis Rheum. 2000, 43(10), 2265–75.
   PubMedGoogle Scholar
• Kinoshita, T., Takeda, J., Hong, K., et al. Monoclonal antibodies to mousecomplement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J. Immunol. 1988, 140(9), 3066–72.
   PubMedGoogle Scholar
• Kurtz, C.B., O’Toole, E., Christensen, S.M., Weis, J.H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J. Immunol 1990, 144(9), 3581–91.
   PubMedGoogle Scholar
• Molina, H., Kinoshita, T., Inoue, K., et al. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J. Immunol. 1990, 145(9), 2974–83.
   PubMedGoogle Scholar
• Chen, Z., Koralov, S.B., Gendelman, M., et al. Humoral immune responses in Cr2−/− mice: Enhanced affinity maturation but impaired antibody persistence. J. Immunol. 2000, 164(9), 4522–32.
   PubMedGoogle Scholar
• Croix, DA, Ahearn, JM, Rosengard, A.M., et al. Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J. Exp. Med. 1996, 183(4), 1857–64.
   PubMedGoogle Scholar
• Kopf, M., Abel, B., Gallimore, A., et al. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med. 2002, 8(4), 373–8.
   PubMedGoogle Scholar
• Suresh, M., Molina, H., Salvato, M.S., et al. Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J. Immunol. 2003, 170(2), 788–94.
   PubMedGoogle Scholar
• Qin, D., Wu, J., Carroll, M.C., et al. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells andCD21 on B cells in the initiation of IgG responses. J. Immunol. 1998, 161(9), 4549–54.
   PubMedGoogle Scholar
• Limb, G.A., Hamblin, A.S., Wolstencroft, R.A., Dumonde, D.C. Selective upregulation of human granulocyte integrins and complement receptor 1 by cytokines. Immunology 1991, 74, 696–702.
   PubMedGoogle Scholar
• Doi, T., Takemura, S., Ueda, M., et al. Suppressed increase of C3 receptors on polymorphonuclear leukocytes by stimulation with C5a in diabetes mellitus. Arerugi 1995, 44, 1223–1228.
   PubMedGoogle Scholar
• Arora, V., Mondal, A.M., Grover, R., et al. Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-gamma and immune complex. Mol. Immunol. 2007, 44, 1722–1728.
   PubMedGoogle Scholar
• Mucida, D., Park, Y., Kim, G., et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007, 317, 256–260.
   PubMed Web of Science ®Google Scholar
• Raju, KR., Sivasankar, B., Anand, V., et al. Use of complement receptor 1 (CD35) assay in the diagnosis and prognosis of immune complex mediated glomerulopathies [J]. Asian Pac J Allergy Immunol, 2001, 19(1), 23–27.
   PubMedGoogle Scholar
• Iida, K., Nussenzweig, V. Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 1981, 153, 1138–1150.
   PubMed Web of Science ®Google Scholar
• Ross, G.D., Lambris, J.D., Cain, J.A., Newman, S.L. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs. CR1 cofactor activity. J. Immunol. 1982, 129, 2051–2060.
   PubMedGoogle Scholar
• Medof, M.E., Nussenzweig, V. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1. J. Exp. Med. 1984, 159, 1669–1685.
   PubMed Web of Science ®Google Scholar
• Yoshida, K., Yukiyama, Y., Miyamoto, T. Interaction between immune complexes and C3b receptors on erythrocytes. Clin. Immunol. Immunopathol. 1986, 39, 213–221.
   PubMedGoogle Scholar
• Cosio, F.G., Shen, X.P., Birmingham, D.J., et al. Evaluation of the mechanisms responsible for the reduction in erythrocyte complement receptors when immune complexes form in vivo in primates. J. Immunol. 1990, 145, 4198–4206.
   PubMedGoogle Scholar
• Craig, M.L., Bankovich, A.J., Taylor, R.P. Visualization of the transfer reaction: Tracking immune complexes from erythrocyte complement receptor 1 to macrophages. Clin. Immunol. 2002, 105, 36–47.
   PubMed Web of Science ®Google Scholar
• van Es, L.A., Daha, M.R. Factors influencing the endocytosis of immune complexes. Adv. Nephrol. Necker Hosp. 1984, 13, 341–367.
   PubMedGoogle Scholar
• Skogh, T., Blomhoff, R., Eskild, W., Berg, T. Hepatic uptake of circulating IgG immune complexes. Immunology 1985, 55, 585–594.
   PubMed Web of Science ®Google Scholar
• Fearon, D.T., Kaneko, I., Thomson, G.G. Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J. Exp. Med. 1981, 153, 1615–1628.
   PubMedGoogle Scholar
• Abrahamson, D.R., Fearon, D.T. Endocytosis of the C3b receptor of complement within coated pits in human polymorphonuclear leukocytes and monocytes. Lab. Invest. 1983, 48, 162–168.
   PubMed Web of Science ®Google Scholar
• Ehlenberger, A.G., Nussenzweig, V. The role of membrane receptors for C3b and C3d in phagocytosis. J. Exp. Med. 1977, 145, 357–371.
   PubMed Web of Science ®Google Scholar
• Schorlemmer, H.U., Hofstaetter, T., Seiler, F.R. Phagocytosis of immune complexes by human neutrophils and monocytes: Relative importance of Fc and C3b receptors. Behring Inst. Mitt. 1984, 88–97.
   PubMedGoogle Scholar
• Sengelov, H., Kjeldsen, L., Kroeze, W., et al. Secretory vesicles are the intracellular reservoir of complement receptor 1 in human neutrophils. J. Immunol. 1994, 153, 804–810.
   PubMedGoogle Scholar
• Fingeroth, J.D., Heath, M.E., Ambrosino, D.M. Proliferation of resting B cells is modulated by CR2 and CR1. Immunol. Lett. 1989, 21, 291–301.
   PubMed Web of Science ®Google Scholar
• Jozsi, M., Prechl, J., Bajtay, Z., Erdei, A. Complement receptor type 1 (CD35) mediates inhibitory signals in human B lymphocytes. J. Immunol. 2002, 168, 2782–2788.
   PubMed Web of Science ®Google Scholar
• Rodgaard, A., Thomsen, B.S., Bendixen, G., Bendtzen, K. Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro. Immunol. Res. 1995, 14, 69–76.
   PubMedGoogle Scholar
• Hamer, I., Paccaud, J.P., Belin, D., et al. Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain. Biochem. J. 1998, 329 (Pt 1), 183–190.
   PubMedGoogle Scholar
• Pascual, M., Duchosal, M.A., Steiger, G., et al. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J. Immunol. 1993, 151, 1702–1711.
   PubMed Web of Science ®Google Scholar
• Hamacher, J., Sadallah, S., Schifferli, J.A., et al. Soluble complement receptor type 1 (CD35) in bronchoalveolar lavage of inflammatory lung diseases. Eur. Respir. 1998, J. 11, 112–119.
   PubMedGoogle Scholar
• Das, N., Sivasankar, B., Tiwari, S.C., et al. Modulation of CR1 expression in glomerulonephritis. Int. Immunopharmacol. 2002, 2 (9), 1386.
   Google Scholar
• Rickert R. C. Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex. Curr.Opinion Immunol. 2005, 17, 237–243.
   PubMed Web of Science ®Google Scholar
• Medof, G. M., Oger Prince, J. Kinetics of interaction of immune complexes with complement receptor on human blood cells: Modification of complexes during interaction with red cells, Clin. Exp. Immunol. 1982, 48, 715–725.
   PubMedGoogle Scholar
• Cornacoff, J.B., Hebert, L.A., Smead, W.L., et al. Primate erythrocyte-immune complex clearing mechanism. J. Clin. Invest. 1983, 71, 236–247.
   PubMed Web of Science ®Google Scholar
• Schifferli, J., Ng, Y., Estreicher, J., Walport, M. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1 dependent mechanisms. J. Immunol. 1988, 140, 899–904.
   PubMed Web of Science ®Google Scholar
• Davies, K., Hird, V., Stewart, S., et al. A study of in vivo immune complex formation and clearance in man. J. Immunol. 1990, 144, 4613–4620.
   PubMed Web of Science ®Google Scholar
• Tausk, F.A., McCutchan, J.A., Spechko, P., et al. Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. J. Clin. Invest. 1986, 78, 977–982.
   PubMed Web of Science ®Google Scholar
• Schifferli, J.A., Ng, Y.C., Paccaud, J.P., Walport, M.J. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin. Exp. Immunol. 1989, 75, 329–335.
   PubMed Web of Science ®Google Scholar
• Davies, K.A., Peters, A.M., Beynon, H.L.C., Walprot, M.J. Immune complex processing in patients with systemic lupus erythematosus. In vivo imaging and clearance studies. J. Clin. Invest. 1992, 90, 2075–2083.
   PubMed Web of Science ®Google Scholar
• Gibson, N.C., Waxman, F.J. Relationship between immune complex binding and release and the quantitative expression of the complement receptor type 1 (CR1, CD35) on human erythrocytes. Clin. Immunol. Immunopathol. 1994, 70, 104–113.
   PubMedGoogle Scholar
• Prechl, J., Erdei, A. Immunomodulatory functions of murine CR1 /2. Immunopharmacology 2000, 49, 117– 124.
   PubMedGoogle Scholar
• Fearon, D.T., Carter, R.H. The CD19/CR2/TAPA-1 complex of B-lymphocytes: Linking natural to acquired immunity. Annu. Rev. Immunol. 1995, 13, 127–149.
   PubMed Web of Science ®Google Scholar
• Tedder, T.F., Zhou, L.-J., Engel, P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today 1994, 15, 437–442.
   PubMedGoogle Scholar
• Ahearn, J.M., Fischer, M.B., Croix, D.A., et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996, 4, 251–262.
   PubMed Web of Science ®Google Scholar
• Carter, R.H., Fearon, D.T. CD19: Lowering the threshold for antigen receptor stimulation of B-lymphocytes. Science 1992, 256, 105–107.
   PubMed Web of Science ®Google Scholar
• Boackle, S.A., Holers, V.M., Chen, X., et al. Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001, 15, 775–785.
   PubMed Web of Science ®Google Scholar
• Prodeus, A., Goerg, S., Shen, L.-M., et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998, 9, 721–731.
   PubMed Web of Science ®Google Scholar
• Wu, X., Jiang, N., Deppong, C., et al. A role for the Cr2 gene in modifying autoantibody production in systemic lupus erythematosus. J. Immunol. 2002, 169, 1587–1592.
   PubMed Web of Science ®Google Scholar
• Cherukuru, A., Cheng, P.C., Sohn, H.W., Pierce, S.K. The CD19/CD21 complex functions to prolong B cell antigen receptor signaling from lipid rafts. Immunity 2001, 14, 169–179.
   PubMedGoogle Scholar
• Cherukuru, A., Pierce, S.K. The role of the CD19/CD21 complex in B cell processing and presentation of complement-tagged antigens. J. Immunol. 2001, 167, 172.
   Google Scholar
• Aubry, J.P., Pochon, S., Graber, P., Jansen, K.U., Bonnefoy, J.Y. CD21 is a ligand for CD23 and regulates IgE production. Nature 1992, 358, 505–507.
   PubMed Web of Science ®Google Scholar
• Kishimoto, T.K., O’Connor, K., Lee, A., Roberts, T.M., Springer, T.A. Cloning of the B subunit of the leukocyte adhesion proteins: Homology to an extracellular matrix receptor defines a novel supergene family. Cell 1987, 48, 681–690.
   PubMed Web of Science ®Google Scholar
• Brown, E.J. Complement receptors and phagocytosis. Curr. Opin. Immunol. 1991, 3, 76–82.
   PubMed Web of Science ®Google Scholar
• Rezonnico, R., Chicheportiche, R., Imbert, V., Dayer, J.M. Engagement of CD11b and CD11c beta2 integrin by antibodies or soluble CD23 induces IL-1beta production on primary human monocytes through mitogen-activated protein kinase-dependent pathways. Blood 2000, 95, 3877.
   Google Scholar